SHANDONG BUCHANG PHARMACEUTICALS CO., LTD.

Shandong Buchang Pharmaceuticals Co., Ltd.

603858

CNE100002FV6

Pharmaceuticals

End-of-day quote Shanghai S.E. Other stock markets 03:30:00 17/07/2024 am IST			5-day change	1st Jan Change
15.08 ^CNY	+0.13%		+3.36%	-11.35%

15/06	Shandong Buchang Pharmaceuticals Co., Ltd. announces an Increase in Equity Buyback.	CI
29/05	Shandong Buchang Pharmaceuticals Gets China Nod for Cholesterol Control Tablets	MT

Bank of Chaoyang Co., Ltd. announced that it has received CNY 715.5792 million in funding from Shandong Buchang Pharmaceuticals Co., Ltd., Guocheng Mining Co., Ltd. and other investors

January 03, 2019

On January 3, 2019, Bank of Chaoyang Co., Ltd. completed the transaction. The company completed its change of business registration of its capital increase.

Latest news about Shandong Buchang Pharmaceuticals Co., Ltd.

Shandong Buchang Pharmaceuticals Co., Ltd. announces an Increase in Equity Buyback.	15/06	CI
Shandong Buchang Pharmaceuticals Gets China Nod for Cholesterol Control Tablets	29/05	MT
Shandong Buchang Pharmaceuticals Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024	25/04	CI
Shandong Buchang Pharmaceuticals Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023	25/04	CI
Tranche Update on Shandong Buchang Pharmaceuticals Co., Ltd.'s Equity Buyback Plan announced on December 14, 2023.	02/04	CI
Buchang Pharma Obtains Green Light to Trial Gastric Cancer Drug Combination	28/02	MT
Tranche Update on Shandong Buchang Pharmaceuticals Co., Ltd.'s Equity Buyback Plan announced on December 14, 2023.	03/01	CI
Buchang Pharma’s Drugs Retain National Medical Insurance Coverage	15/12	MT
Shandong Buchang Pharmaceuticals Co., Ltd. announces an Equity Buyback for CNY 360 million worth of its shares.	14/12	CI
Shandong Buchang Pharmaceuticals Co., Ltd. authorizes a Buyback Plan.	13/12	CI
Buchang Pharma's Unit Gets Nod to Test Colorectal Cancer Drug	09/11	MT
Shandong Buchang Pharmaceuticals Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2023	27/23/27	CI
Haikou Xinyingyang Investment Partnership Enterprise (Limited Partnership) and Xi Chong agreed to acquire 14% stake in Buchang Health Industry (Zhejiang ) Co., Ltd. from Shandong Buchang Pharmaceuticals Co., Ltd.,Hu Cunchao, Li Hui, and Hu Cunchao for CNY 0.	07/23/07	CI
Buchang Pharma Unit Gets Nod to Trial Cancer Treatment	04/23/04	MT
Shandong Buchang Pharmaceuticals Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2023	25/23/25	CI
Selling Expenses of Chinese Listed Pharma Companies About 1.5x Higher Than Net Profits in 2022	10/23/10	MT
Buchang Pharmaceuticals to Set Up Medical Device Subsidiary	08/23/08	MT
Buchang Pharma Unit Gets Nod to Make Amendments to Diabetes Drug	14/23/14	MT
Buchang Pharmaceuticals to Invest 223 Million Yuan Into Old Factory Upgrade	13/23/13	MT
Buchang Pharma's Unit Passes Regulator's Good Manufacturing Practice Evaluation	05/23/05	MT
Zhao Yunhua agreed to acquire a 90% stake in Buchang Taoyiyun Health Technology Co., Ltd. from Shandong Buchang Pharmaceuticals Co., Ltd. for CNY 1.	29/23/29	CI
Ningbo Buchang Medical Technology Co., Ltd. announced that it expects to receive CNY 3 million in funding from Shandong Buchang Pharmaceuticals Co., Ltd., Shaanxi Deju Bowen Health Technology Co., Ltd.	27/23/27	CI
Buchang Pharma Unit Passes Regulatory Inspection	22/23/22	MT
Buchang Pharma Unit Gets Nod for Flu Vaccine Trials in China	20/23/20	MT
Shandong Buchang Pharmaceuticals Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2022	27/23/27	CI

Chart Shandong Buchang Pharmaceuticals Co., Ltd.

Duration

Period

Chart Shandong Buchang Pharmaceuticals Co., Ltd.

More charts

SHANDONG BUCHANG PHARMACEUTICALS CO., LTD. is a China-based company principally engaged in the research, development, manufacture and distribution of Chinese patent medicines. The Companyâs main products are compound traditional Chinese medicines, including cerecarton capsules,wenxin granules, as well as danhong injections, among others. Its products are mainly applied to the fields of cardio-cerebrovascular diseases and gynecological diseases. The Company distributes its products within domestic market and to overseas markets, with North China, East China and Central China as its major markets.

Sector

Pharmaceuticals

Calendar

23/08/2024 - Q2 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Annual profits - Rate of surprise

Company calendar

Sector Alternative Medicine

	1st Jan change	Capi.
SHANDONG BUCHANG PHARMACEUTICALS CO., LTD.	-11.35%	227.13Cr
DONG-E-E-JIAO CO.,LTD.	+7.30%	480.69Cr
SHIJIAZHUANG YILING PHARMACEUTICAL CO., LTD.	-31.08%	359.73Cr
TIANJIN PHARMACEUTICAL DA REN TANG GROUP CORPORATION LIMITED	-0.71%	308.96Cr
TASLY PHARMACEUTICAL GROUP CO., LTD	-24.32%	262.23Cr
HENAN LINGRUI PHARMACEUTICAL CO., LTD.	+34.19%	181.51Cr
ZHEJIANG JOLLY PHARMACEUTICAL CO.,LTD	+33.49%	141.17Cr
TIBET CHEEZHENG TIBETAN MEDICINE CO., LTD.	-15.07%	137.88Cr
PT INDUSTRI JAMU DAN FARMASI SIDO MUNCUL TBK	+40.95%	137.25Cr
TIANJIN CHASE SUN PHARMACEUTICAL CO.,LTD	-25.94%	129.04Cr

Alternative Medicine

Shandong Buchang Pharmaceuticals Co., Ltd.

Equities

603858

CNE100002FV6

Pharmaceuticals

Bank of Chaoyang Co., Ltd. announced that it has received CNY 715.5792 million in funding from Shandong Buchang Pharmaceuticals Co., Ltd., Guocheng Mining Co., Ltd. and other investors

Latest news about Shandong Buchang Pharmaceuticals Co., Ltd.

Chart Shandong Buchang Pharmaceuticals Co., Ltd.

Company Profile

Income Statement Evolution

Annual profits - Rate of surprise

Sector Alternative Medicine